Business Activity Statement & Appendix 4C - Dec-2024 Qtr

Key points

• Net Revenue: $1.8 million, down 4% from Q4 FY'23
• Shipments to US ECPs: $1.9 million, up 6% from Q4 FY'23
• Cash receipts from customers: $2.2 million, up 36% from Q4 FY'23

Full summary

Visioneering Technologies Inc. (ASX:VTI), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, announced its unaudited results for the quarter ended 31 December 2024. Net Revenue was $1.8 million, down 4% from Q4 FY'23, while Shipments to US ECPs were $1.9 million, up 6% from Q4 FY'23. Cash receipts from customers were $2.2 million, up 36% from Q4 FY'23. Net cash used in operating activities was $0.6 million, a 59% decrease compared to Q4 FY'23. Gross margin was 57.1%, up from 57.0% in Q4 FY'23. The company's PROTECT Randomized Clinical Trial showed sustained myopia progression control, and the NaturalVue® Multifocal 1 Day Contact Lense was recognized with the prestigious Optician Award in the UK. Visioneering continues to expand internationally, signing agreements for Europe, Vietnam, and South Korea.